Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
about
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacyAn antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaquesA Comparison of Lower Genital Tract Glycogen and Lactic Acid Levels in Women and Macaques: Implications for HIV and SIV SusceptibilityA review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infectionsTargeting Trojan Horse leukocytes for HIV prevention.Development of topical microbicides to prevent the sexual transmission of HIVIdentification of rhesus macaque genital microbiota by 16S pyrosequencing shows similarities to human bacterial vaginosis: implications for use as an animal model for HIV vaginal infection.Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: searching for more potent microbicidesA guide for standardizing colposcopic observations for the evaluation of topical microbicide products in the pigtailed macaque model.Rectal microbicide development.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model.Pigtailed macaque model refinement: topical microbicide safety in the presence of coitusNon-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.Gene Expression Profiling of Human Vaginal Cells In Vitro Discriminates Compounds with Pro-Inflammatory and Mucosa-Altering Properties: Novel Biomarkers for Preclinical Testing of HIV Microbicide Candidates.Testing of viscous anti-HIV microbicides using Lactobacillus.Microbicides for HIV prevention.Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.The Effects of Hormones and Vaginal Microflora on the Glycome of the Female Genital Tract: Cervical-Vaginal FluidUC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal applicationFactors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humansInfluence of Ethanol as a Co-Solvent in Cyclodextrin Inclusion Complexation: A Molecular Dynamics Study.Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assayPharmacologic opportunities for HIV prevention.Microbicides: still a long road to successVaginal drug delivery systems for HIV prevention.The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract.RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.Pharmaceutical development of microbicide drug products.Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.Non-human primate models of hormonal contraception and HIV.Predicting the unpredictable real-world impact of ARV-based microbicides.
P2860
Q21135264-85A40461-3237-4840-ACEF-7D8A158BD7B2Q27438093-A03462DF-0782-4D16-860B-B61D073C18DEQ29999391-0B13D7AA-F6FC-4B3B-986A-75330A19ADEEQ30369008-2929DB07-E43B-44B0-89E6-3F5493CD0276Q33518390-F7977E8F-3699-4163-ADB4-0D0405A0452FQ33625073-0D105838-D87A-4220-9B5F-C4B68F1847AAQ33714529-6C688247-A40D-468C-9BB1-5486AB591DE8Q34005632-5409EA41-02CC-40AA-8A99-A4AD4D3ABD11Q34392634-0181637E-B49A-4802-81F7-D6C677613272Q34575590-75841D7B-3DBF-4D2F-AD70-64593BE6A04DQ34737547-9A296B7C-2F88-40AD-B4B1-A41ADB77A4E8Q34989166-63D6A3C8-CC6D-4A19-A746-646653897C7FQ35083897-F1253A10-B08E-4D72-8650-98EFF539D0D3Q35563416-382697D6-3E65-4E67-A0AB-EA1C14F85803Q35619304-3185E780-B4E3-4230-929E-70BC2277865BQ35656128-132463DB-219E-4996-8DE4-F526AEDC6386Q35734254-8C9B806E-2E1F-43EE-A39E-55C62B7BED8FQ35770899-FA1ACF18-8AF5-49EC-A6EF-8C00790AD950Q36018776-C0C1B6B2-8F18-4E2E-958A-82F5B6A570ABQ36082673-FC97BB6A-1C3B-4DBA-96ED-C60DD8FB389FQ36086344-F4D901A0-DCD0-4AF4-9BC8-3B4CC60C3022Q36111516-32BB8EC9-2DEF-4141-A637-A6B2DC74E644Q36113575-D6F1D475-CCBC-47C8-BA5E-FFC06A7C6A3CQ36250396-1305E6FF-7D36-486E-A3E3-20CA8FA6485AQ36504995-F24662E3-F8C6-4077-BAA1-2D5A8AD15A71Q36803970-068C6FBC-4453-43BC-B5A2-FA7F76C23095Q36905431-E51E9655-BF99-4EF3-ADDB-E48A615A7DF7Q37130757-62EDD2FB-51CE-47FF-826A-BFF76EDDA6FBQ37149107-21FA3226-BE51-4448-B9A1-C8163F55C30AQ37210863-34E3B28B-B925-4F02-B227-DEA83BC4274EQ37428359-7814B21A-BD09-47E7-90D3-D8A26FD28FAAQ37657468-C35F188A-AD60-4D2F-B310-16113A3D8FDDQ37707803-F2976F32-4353-4680-93C1-7F81536C8B69Q42225882-96336905-1513-44AF-8A10-33938637FE29Q43233038-6D35508A-E23C-4813-86C1-6B720880158F
P2860
Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Preclinical safety assessments ...... ical microbicide formulations.
@ast
Preclinical safety assessments ...... ical microbicide formulations.
@en
type
label
Preclinical safety assessments ...... ical microbicide formulations.
@ast
Preclinical safety assessments ...... ical microbicide formulations.
@en
prefLabel
Preclinical safety assessments ...... ical microbicide formulations.
@ast
Preclinical safety assessments ...... ical microbicide formulations.
@en
P2093
P2860
P356
P1476
Preclinical safety assessments ...... ical microbicide formulations.
@en
P2093
B J Moncla
D L Patton
J E Balkus
M A Parniak
S L Hillier
Y T Cosgrove Sweeney
P2860
P304
P356
10.1128/AAC.00984-06
P407
P577
2007-03-12T00:00:00Z